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Introduction
Int ensive insulin therapies for diabetes mellitus requiring frequent self-monitoring of blood glucose often fail to reduce glycosylated hemoglobin (HbA1c) to target levels, resulting in continued high prevalence of microvascular and macrovascular complications. 1, 2 Limitations of these regimens include increased hypoglycemic episodes, occult postprandial hyperglycemia or nocturnal hypoglycemia, and variable adherence related to pain or inconvenience associated with SMBG. In addition, patients may also be fearful of experiencing hypoglycemia.
Advances in continuous glucose monitoring (CGM) have allowed progression from providing retrospective data only to ongoing real-time assessment of interstitial fluid glucose concentrations. Newer alarm functions present in current real-time personal use CGM devices can alert the patient to trends such as rapid decreases in glucose levels, with the goal being prevention of severe hypoglycemia. 3 These supplementary data may allow for more precise insulin administration to improve glycemic control, minimize symptomatic excursions from euglycemia, and limit the emotional impact and possible morbidity associated with such variations.
However, results of previous studies attempting to prove efficacy of these devices have been mixed. Most of these studies have been small and restricted to limited subsets of people with diabetes. Two prior systematic reviews completed on this topic failed to demonstrate significant reductions in HbA1c with use of CGM. 4, 5 Since the time of publication of these systematic reviews, there have been additional randomized controlled trials (RCTs) performed, including the largest CGM trial to date (322 patients). 3 As new CGM technologies are invasive and expensive and provide large volumes of data to patients, these devices could have unintended consequences in relation to patient treatment satisfaction, emotional well-being, and health care resource utilization. To synthesize evidence, we undertook a systematic review and meta-analysis of RCTs to evaluate the efficacy and safety of CGM compared to SMBG with regards to improving glycemic control and reducing hypoglycemia in both adult and pediatric populations with type 1 and type 2 diabetes mellitus (T1DM and T2DM).
Methods
The report of this protocol-driven systematic review follows recommendations by the Cochrane collaboration 6 and is reported following the standards set by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. 7 
Eligibility Criteria
We included RCTs of adults and children with T1DM or T2DM in the outpatient setting. Literature search did not discriminate between different types of CGM; both real-time and non-real-time CGM devices were included. The control groups needed to utilize SMBG. We included RCTs regardless of their publication status, language, size, or primary objective. We excluded trials that did not have sufficient follow-up (8 weeks), were conducted in inpatient settings, had different methods of insulin Abstract cont.
Conclusion:
Continuous glucose monitoring seems to help improve glycemic control in adults with T1DM and T2DM. The effect on hypoglycemia incidence is imprecise and unclear. Larger trials with longer follow-up are needed to assess the efficacy of CGM in reducing patient-important complications without significantly increasing the burden of care for patients with diabetes.
Study Identification
Expert reference librarian Patricia J. Erwin designed and conducted the electronic search strategy with input from study investigators with expertise in conducting systematic reviews. To identify eligible studies, we searched electronic databases (MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science, and Scopus) from 1996 to November 15, 2010. A combination of medical subject headings and text words were utilized. The detailed search strategy is available from the corresponding author.
Assessment of Study Eligibility
Pairs of reviewers independently screened all abstracts and titles and selected potentially eligible studies for fulltext assessment. The process was repeated in duplicate for full-text review. Disagreements were resolved by consensus or arbitration. Kappa for study selection was 0.80.
Data Collection
Working in duplicate, a standardized form was used to extract data on study characteristics: description of participants, age, gender, number of patients involved, type of CGM, duration and frequency of use, and type of SMBG used. We also extracted outcomes of interest: HbA1c, time hyperglycemic and hypoglycemic, incidence of severe hyperglycemia and hypoglycemia, incidence of nocturnal hypoglycemia, emergency medical service utilization for extremes of glycemia, and patient satisfaction of CGM. Reviewers also appraised the methodological quality of eligible RCTs, considering adequacy of allocation concealment, blinding of patients, health care providers, data collectors and outcome assessors, if an RCT was stopped early, and the extent of loss to follow-up (i.e., proportion of patients in whom the investigators were unable to ascertain outcomes). For each of these variables, we used results reported in the original RCTs, thus accepting the authors' definitions of these terms. When needed, we contacted authors of the studies included by email to obtain missing data or confirm data we had extracted.
Statistical Analysis
We estimated the effect of CGM from each study with 95% confidence interval (CI) using the weighted mean difference (WMD) for continuous outcomes and the relative risk (RR) for dichotomous outcomes. The former measure retains the original data units and the latter is a unitless ratio. An event rate ratio was estimated if a study reported hypoglycemic and hyperglycemic events per period of time. The estimates from each study were pooled using a random-effects model 8 incorporating the between-study heterogeneity as well as the withinstudy heterogeneity. The extent of heterogeneity was assessed using the I 2 statistic. 9 Interaction between subgroups was tested using an interaction test 10 and metaregression. A priori established subgroup analyses were based on the type of CGM (real-time versus non-realtime), loss to follow up, and adherence monitoring. To assess publication bias, we planned to inspect funnel plots visually and test their symmetry statistically using Egger's regression test.
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Results
Search Results
A total of 990 references were screened as abstracts and 150 of them were deemed potentially eligible. Full-text review of these 150 references resulted in exclusion of 131 references (18 were not original research reports, 113 were nonrandomized). Table 1 describes the characteristics of the 19 trials that enrolled 1801 patients. The baseline HbA1c was at least greater than 7.0% (the vast majority were greater than 8%) in all studies but one, 12 in which patients had a mean baseline HbA1c of 6.4%.
As expected, mean age in studies enrolling people with T1DM was younger compared to those with T2DM. Duration and frequency of CGM use was quite variable. Type and frequency of SMBG, although often not well reported, lacked similarity in general between the studies. Two included studies had crossover study design. 13, 14 The methodological quality of the trials ( Table 2 ) was fair, with only 2 in 19 definitively reporting allocation concealment, a feature that protects the randomization by concealing the allocation sequence from the investigator enrolling patients. The range of loss to follow-up was 0% to 19%.
After visually evaluating funnel plots and statistically testing their symmetry, we could not find evidence for publication bias; however, the number of included studies is quite small, making these methods highly underpowered. In fact, publication bias is quite likely present considering the small size of most of the studies. in studies of children and adolescents (55%) and low in studies of adults with T2DM (0%) and T2DM (0%) diabetes (Figure 1 ).
Subgroup analysis (Table 3) and meta-regression demonstrate no effect of type of CGM used (real-time versus non-real-time). Studies with potentially lower quality (higher loss to follow-up, no adherence monitoring) are associated with exaggerated treatment effect (benefit). 
Adverse Effects
No significant adverse effects related to the device were reported in any of the trials. Data on the incidence of severe hypoglycemia, hyperglycemia, nocturnal hypoglycemia, or severe hyperglycemia were very sparse, poorly reported, and imprecise. The RR for hypoglycemia (based on number of patients suffering at least one episode of hypoglycemia as the unit of analysis) was 1.02 (95% CI, 0.3 to 3.45). Using the number of events as the unit of analysis, the rate ratio for hypoglycemia was 3.50 (95% CI, 1.07 to 11.44) and for hyperglycemia 1.42 (95% CI, 0.26 to 7.82) (Figures 2 and 3) . The definitions and conclusions regarding hypoglycemia are presented for individual studies in Table 4 . Hypoglycemia was the primary end point of one study 12 in which patients had good glycemic control at baseline.
Other Patient-Important Outcomes
Patient satisfaction and feasibility were reported in seven trials; these outcomes are reported in Table 5 qualitatively, because meta-analysis of these outcomes was not feasible due to heterogeneity of outcome assessment and reporting. 15, 17, 19, 25, [27] [28] [29] Studies used acceptance questionnaires relating to specific features of the study arm treatment system. Results generally were favorable to the CGM. Study participants rated CGM as being superior to their previous monitoring system and recommended its use to others. Quality-of-life measures did not change with the use of CGM. 31 Some concerns were raised about the technical functioning of the devices (mainly GlucoWatch). Some participants in the studies stopped wearing the continuous glucose sensors because of inconvenience, problems sleeping, bathing, and difficulty taking part in sporting activities. Excluded; none had severe hypoglycemia in previous 6 months, but many had had a seizure in past secondary to hypoglycemia CGM increased hypoglycemia detection (significantly) compared with the control group; the greatest relative increase in detection of hypoglycemia was at night in CGM patients wearing the device; data are represented as event rates/100 patient hours One participant in the intervention group admitted to hospital for new-onset depression. Mechanical problems noted in five participants using CGM. Five withdrew in intervention group: burden of recurrent alarms (n = 2), significant skin irritation (2), inability to maintain skin adhesion due to perspiration.
Cooke, 2009
17 By 18-month follow-up, 80% of the GlucoWatch group and 33% of the CGMS group had stopped using their devices. The most common reasons for stopping use in the GlucoWatch group were skin reactions (49%) followed by difficulties with the devices (10%). In the CGMS group, the main reasons for stopping use were more varied, including inconvenience, problems sleeping, and difficulty taking part in sporting activities.
Cosson, 2009 18
The only adverse events related to the device over the 68 CGM periods were four (5.8%) cases of uncomplicated implantation-site skin reactions, which required no specific treatment. The tolerability questionnaires found that pain during sensor implantation was nonexistent, mild, moderate, and severe in 54%, 38%, 6%, and 1%, respectively, and the bulkiness of the device was bothersome during usual day-to-day activities in 37%, 24%, 29%, and 10% patients, respectively. Yoo, 2008 19 Nearly all felt confident about the device.
Chase, 2005 25 At the 6-month visit, the reasons for not using the GlucoWatch G2 Biographer included skin irritation (76%), skips too frequently (56%), alarms too frequently (47%), and does not provide accurate readings (33%). Participants were "mildly dissatisfied" with use of the GlucoWatch G2 Biographer and attributed dissatisfaction to the technical functioning of the device than the psychological ramifications of using it.
Chase, 2003 27 Each participant completed the Fear of Hypoglycemia and the DCCT Quality of Life questionnaires. There were no significant differences in either scale between the control and Biographer groups during the intervention phase of the study.
Chico, 2003 28
Patients felt confident and satisfied with CGMS use (not quantified). Only five patients had difficulty with system instructions. No skin lesions, although eight patients felt some discomfort.
Chase, 2001
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There were no significant differences in results for the Fear of Hypoglycemia or the Quality of Life surveys between the test and control participants at any time.
Discussion
Main Findings
This systematic review and meta-analysis suggests that currently available personal real-time CGM devices improve glycemic control in adults with T1DM ot T2DM. As is true for any meta-analysis, pooling from primary studies at risk for bias reduces confidence in the results.
Strengths, Limitations, and Comparison with Other Reviews
Our work has several strengths. We asked focused questions, conducted a comprehensive and systematic literature search using explicit eligibility criteria, made reproducible judgments of eligibility and quality, and conducted a protocol-driven analysis.
The other two systematic reviews covering this topic 4, 5 predominantly included children with T1DM, allowed only Medtronic CGM devices to be included, did not include real-time CGM, and were completed before publication of the largest RCT. 3 Our study allowed any brand of CGM and included patients with T1DM and T2DM.
The current body of literature suffers from several shortcomings. Device studies in general are structured to demonstrate a maximal difference in the outcome and will often provide more education, visits, support, feedback, and access to patients in the device group. This can result in a co-intervention effect and bias that exaggerates the treatment effect. This additional support is not well-documented in the published manuscripts and was hard to ascertain and thus remains a concern for the internal validity of the studies and poses a real challenge to applicability and evidence translation. The documentation of hypoglycemia was heterogeneous across studies (e.g., per patient, per event, percentage of time spent in hypoglycemic range, varying definitions of hypoglycemia, and no stratification according to severity of hypoglycemia), limiting the ability to conduct meaningful meta-analysis. Also, CGM technology changes rapidly, making evidence synthesis challenging. In this meta-analysis, the majority of the included trials did not conceal allocation. The inference is also limited by the small number of RCTs in patients who used the currently available CGM devices. There is much heterogeneity in the reporting of hyperglycemia and hypoglycemia, making it difficult to draw collective inferences that are helpful to clinicians. Therefore, the strength of the current evidence is low to moderate. 32 Most of the studies included used devices manufactured by one company. Thus there could be differences between the different sensors available regarding insertion device, size precision, lag time that may affect patient satisfaction, and results. Adults included in these studies tended to be fairly young. It is difficult to extrapolate the findings to geriatric patients, and use of this technology may not have the same desirable findings as in younger adults. In the studies included, the number of patients with T2DM is rather low, and thus, meaningful translation of evidence of reducing HbA1c in that population is limited because of sparse data. Many of the GlucoWatch studies were done in children. Children and adolescents may use continuous glucose sensors less frequently. It has been observed that sensor use is related to effect size. For these reasons, the present meta-analysis may not have found a significant improvement in HbA1c in children and adolescents.
Recommendations for Research and Practice
Future trials should explicitly report the education and support provided to both study arms. Perhaps a standardized score of such support could be provided and validated for all device trials across specialties. Hypoglycemia should be reported uniformly with standard cutoffs and definitions of severity (minor, resolving without treatment, requiring treatment, or requiring third party assistance) and, preferably, results are reported per patient as opposed to per event. 33 While we await a clinically applicable closed-loop automated pancreas or a cure for diabetes, real-time CGM seems to assist certain patients with glycemic control. It may prevent glycemic excursions and variability and may prevent life-threatening hypoglycemic events. It is challenging to make clinically important generalizations from these data regarding hypoglycemia. Perhaps CGM prevented symptomatic hypoglycemia by warning patients of trends prior to an adverse event, making the overall incidence low. However, with blood glucose readings being presented to patients every few minutes, subjects utilizing real-time CGM are bound to have more acknowledged asymptomatic readings that fall below any definition of hypoglycemia used compared to SMBG patients. Finally, and aside from hypoglycemic events, CGM may also lower the time spent in hyperglycemic state and reduce glucose variability in general. 3, 19 The general sense from studies that directly assessed patient satisfaction with CGM 18, 19 was that, overall, patients were satisfied with the devices and recommended their use to others; however, in some studies, we also saw large declines in the use of CGM devices, 3, 16 which may underlie part of the rationale as to why certain groups of patients did not seem to benefit, particularly adolescents. 3 Also, satisfaction with a device within volunteers and perhaps early technology adopters does not necessarily transfer to satisfaction among patients who have different expectations and interests. There may be some disconnect between directly asking how satisfied a patient is with this particular technology and what causes them to discontinue actively using it. One study adjusted for compliance 20 and found that compliance of more than 60% was associated with significant reduction in HbA1c compared to those with lower level of compliance. Thus careful selection of patients who may benefit from this technology-by virtue of their enthusiasm, interest, and skills-and adequate support systems may enhance the results seen in clinical trials and inform health care delivery systems in the future. Social and psychological factors also can affect the use of this technology and can help in choosing appropriate candidate individuals. In a qualitative study, the involvement of significant others, such as a spouse, and presence of adequate coping skills were factors identified to be associated with increased CGM use. 34 Guidelines and technologies for interpreting large volumes of CGM data could improve the counseling and management support that follows CGM use. The impact of CGM across patients of different age and diabetes type remains largely uncertain. Optimal frequency and duration of CGM use are unknown. Finally, the cost-effectiveness of CGM is yet to be determined. Preliminary analyses projected that long-term use of CGM is cost-effective among patients with T1DM at the $100,000/quality-adjusted life year threshold; these estimates, however, are very sensitive to the various modeling assumptions and are surrounded by great uncertainty.
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Conclusion
Real-time CGM lowers HbA1c in adult patients with T1DM and T2DM and has no discernible impact in other patients with diabetes. Potential benefits of these technologies need to be considered in light of the burden it places on patients, clinicians, and health systems.
